Clinical Trial Coordinator
TOBY
Summary
TOBY profiles Volatile Organic Compounds (VOCs) in urine using spectroscopy and AI to detect disease early. Our goal is to build diagnostics that are noninvasive, affordable, and scalable.
Job description
About TOBY
TOBY profiles Volatile Organic Compounds (VOCs) in urine using spectroscopy and AI to detect disease early. Our goal is to build diagnostics that are noninvasive, affordable, and scalable.
The Role
We need someone to own day-to-day execution of our studies from site startup through ongoing operations. You'll coordinate sites, keep study activities and data on track, and manage the flow of samples through the lab. This is a hands-on role with broad responsibility and direct access to the leadership team.
What You Will Do
- Lead day-to-day operations of multi-site studies, including site startup, timelines, and follow-up
- Serve as the main operational contact for study sites and coordinate with investigators and site teams
- Track study documentation, approvals, enrollment, samples, and milestones
- Oversee study data workflows in the EDC, review data for completeness and consistency, and coordinate resolution of questions with sites
- Coordinate lab operations, including sample receipt, tracking, testing schedules, documentation, and communication between the study sites and lab
- Identify operational issues early and build processes that help the study and lab run reliably
Requirements
- Experience coordinating or running clinical research studies, ideally across multiple sites
- Strong project coordination skills; able to manage timelines, documentation, follow-up, and competing priorities
- Comfortable working with EDC systems, study records, and data quality review
- Familiarity with clinical research, IRB processes, informed consent, and human-subject protections
- Experience coordinating clinical or research laboratory workflows is a plus
Company overview
TOBY, Inc. is a privately held biotechnology company founded in 2023 and headquartered in Austin, Texas (with roots in New York City). Named after Sherlock Holmes's trusted bloodhound, TOBY is pioneering non-invasive, urine-based cancer screening by combining volatilomics—the profiling of volatile organic compounds (VOCs)—with mass spectrometry and proprietary artificial intelligence. Its platform is designed to detect more than ten cancers from a single urine sample, representing over 60% of global cancer cases, with the goal of making early detection routine, accessible, and precise. TOBY's technology has earned FDA Breakthrough Device Designation for both its bladder cancer test and its urine-based Multi-Cancer Early Detection (MCED) platform—the first urine-based MCED technology to receive this designation. Backed by investors including LifeX Ventures, MassChallenge Israel, and Arizona State University, and supported by accelerators such as the Mayo Clinic and ASU MedTech Accelerator, TOBY is advancing clinical validation toward broad clinical adoption.